Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

PS01.63: Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC): Topic: Medical Oncology.

Shah S, Wood K, Brisson R, Karrison T, Hensing T, Luke JJ, Patel JD.

J Thorac Oncol. 2016 Nov;11(11S):S310. doi: 10.1016/j.jtho.2016.09.098. Epub 2016 Oct 28. No abstract available.

2.

KRAS in Non-Small-Cell Lung Cancer-Reply.

Wood K, Hensing T, Salgia R.

JAMA Oncol. 2016 Oct 1;2(10):1373-1374. doi: 10.1001/jamaoncol.2016.2347. No abstract available.

PMID:
27442777
3.

Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.

Campbell NP, Hensing TA, Bhayani MK, Shaikh AY, Brockstein BE.

Expert Rev Anticancer Ther. 2016 Aug;16(8):847-58. doi: 10.1080/14737140.2016.1202116. Epub 2016 Jul 11. Review.

PMID:
27400139
4.

Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.

Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.

5.

Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.

Wood K, Hensing T, Malik R, Salgia R.

JAMA Oncol. 2016 Jun 1;2(6):805-12. doi: 10.1001/jamaoncol.2016.0405. Review.

PMID:
27100819
6.

The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative.

Won B, Carey GB, Tan YH, Bokhary U, Itkonen M, Szeto K, Wallace J, Campbell N, Hensing T, Salgia R.

Cureus. 2016 Mar 16;8(3):e533. doi: 10.7759/cureus.533.

7.

Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation.

Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R.

Oncotarget. 2016 Apr 5;7(14):18876-86. doi: 10.18632/oncotarget.7739.

8.

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G.

J Clin Oncol. 2016 Mar 20;34(9):987-1011. doi: 10.1200/JCO.2015.65.8427. Epub 2016 Feb 4. No abstract available.

9.

Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit.

Rosenberg CA, Flanagan C, Brockstein B, Obel JC, Dragon LH, Merkel DE, Wade EL, Law TM, Khandekar JD, Hensing TA.

J Cancer Surviv. 2016 Feb;10(1):206-19. doi: 10.1007/s11764-015-0467-6. Epub 2015 Jul 16.

PMID:
26178325
10.

Lung cancer-a fractal viewpoint.

Lennon FE, Cianci GC, Cipriani NA, Hensing TA, Zhang HJ, Chen CT, Murgu SD, Vokes EE, Vannier MW, Salgia R.

Nat Rev Clin Oncol. 2015 Nov;12(11):664-75. doi: 10.1038/nrclinonc.2015.108. Epub 2015 Jul 14. Review.

11.

Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung.

Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR.

Oncoscience. 2014 Aug 7;1(8):522-528. eCollection 2014.

12.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R.

J Thorac Oncol. 2015 Jan;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405.

13.

Outpatient advance care planning for patients with metastatic cancer: a pilot quality improvement initiative.

Obel J, Brockstein B, Marschke M, Robicsek A, Konchak C, Sefa M, Ziomek N, Benfield T, Peterson C, Gustafson C, Eriksson J, Harper A, Tabachow C, Raymond M, Hensing T.

J Palliat Med. 2014 Nov;17(11):1231-7. doi: 10.1089/jpm.2014.0085. Epub 2014 Oct 24.

PMID:
25343403
14.

Buccal spectral markers for lung cancer risk stratification.

Radosevich AJ, Mutyal NN, Rogers JD, Gould B, Hensing TA, Ray D, Backman V, Roy HK.

PLoS One. 2014 Oct 9;9(10):e110157. doi: 10.1371/journal.pone.0110157. eCollection 2014.

15.

Buccal microRNA dysregulation in lung field carcinogenesis: gender-specific implications.

Wali RK, Hensing TA, Ray DW, Dela Cruz M, Tiwari AK, Radosevich A, Jepeal L, Fernando HC, Litle VR, Charlot M, Momi N, Backman V, Roy HK.

Int J Oncol. 2014 Sep;45(3):1209-15. doi: 10.3892/ijo.2014.2495. Epub 2014 Jun 11.

16.

Molecular pathways and therapeutic targets in lung cancer.

Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R.

Oncotarget. 2014 Mar 30;5(6):1392-433. Review.

17.

A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization.

Hensing T, Chawla A, Batra R, Salgia R.

Adv Exp Med Biol. 2014;799:85-117. doi: 10.1007/978-1-4614-8778-4_5. Review.

PMID:
24292963
18.

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA.

J Clin Oncol. 2013 Sep 20;31(27):3320-6. doi: 10.1200/JCO.2013.51.1816. Epub 2013 Aug 26.

19.

Molecular biomarkers for future screening of lung cancer.

Hensing TA, Salgia R.

J Surg Oncol. 2013 Oct;108(5):327-33. doi: 10.1002/jso.23382. Epub 2013 Jul 25. Review.

PMID:
23893423
20.

Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE.

Chest. 2013 May;143(5 Suppl):e341S-e368S. doi: 10.1378/chest.12-2361.

Supplemental Content

Loading ...
Support Center